Effects of bumetanide: A Synthesis of Findings from 24 Studies
- Home
- Effects of bumetanide
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of bumetanide: A Synthesis of Findings from 24 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major Research Findings
Bumetanide is a loop diuretic that has been studied for its potential therapeutic effects on various neurological disorders, including autism spectrum disorder (ASD), epilepsy, and stroke. Bumetanide acts by inhibiting the sodium-potassium-chloride cotransporter (NKCC1), which plays a crucial role in regulating chloride concentration within cells.
One key finding is that bumetanide can improve core symptoms of ASD in children, as demonstrated by a multicenter phase 2B study 8 . This study showed that bumetanide significantly improved scores on the Childhood Autism Rating Scale (CARS), the Social Responsiveness Scale (SRS), and the Clinical Global Impressions (CGI) Improvement scale (CGI-I). Further supporting this potential, a separate study 16 reported that bumetanide reduced autistic behavior in infants. These findings suggest that bumetanide could be a valuable therapeutic agent for ASD.
However, another study 2 found that bumetanide did not improve neurocognitive function in children with ASD. This suggests that bumetanide may not be effective for all ASD symptoms. Furthermore, research on the effects of bumetanide in epilepsy has yielded mixed results. While 19 showed that bumetanide could alleviate seizures in newborn rats, another study 4 found that it was not effective in preventing seizures in adult epileptic mice. These findings highlight the need for further research to better understand the specific applications and potential limitations of bumetanide in various neurological disorders.
Benefits and Risks
Benefit Summary
Bumetanide has shown potential benefits in treating a variety of neurological disorders, including autism spectrum disorder (ASD), epilepsy, and stroke. 8 and 16 suggest that bumetanide can improve core symptoms of ASD in children. Bumetanide might also play a role in improving the effects of other anti-seizure medications, as demonstrated in studies using a rat model of birth asphyxia 1 .
Risk Summary
Bumetanide can cause side effects, including hypokalemia (low potassium levels). The frequency and incidence of adverse events are directly correlated with the dose of bumetanide 8 . Additionally, bumetanide has limited penetration into the brain, potentially requiring higher doses to be effective. These factors highlight the importance of careful monitoring and dose adjustment under the guidance of a healthcare professional.
Comparison Across Studies
Commonalities Across Studies
Numerous studies have investigated the potential therapeutic effects of bumetanide on various neurological disorders. A common thread across these studies is the proposed mechanism of action: bumetanide inhibits NKCC1, which regulates chloride concentration within cells, thereby impacting the function of neurotransmitters like GABA. This suggests that bumetanide may act by modulating neuronal excitability, potentially reducing symptoms associated with neurological disorders.
Differences Across Studies
Despite the proposed common mechanism, the effectiveness of bumetanide has varied across different studies and neurological conditions. 8 and 16 suggest that bumetanide is beneficial for ASD, but 2 shows no impact on neurocognitive function. Similarly, bumetanide has shown efficacy in neonatal seizure models 19 but not in adult epileptic mice 4 . This disparity in results emphasizes the need for further investigation to understand the specific conditions and patient populations where bumetanide may be most effective.
Consistency and Contradictions of Results
The results regarding the efficacy of bumetanide in neurological disorders have not been entirely consistent. Some studies have shown promising results, while others have not. This inconsistency may be due to factors such as age, specific neurological condition, dosage, and individual patient variations. Further research is needed to clarify the specific circumstances under which bumetanide is most effective.
Implications for Real-World Application
The potential benefits of bumetanide in treating neurological disorders warrant further exploration. However, it's crucial to remember that bumetanide is a prescription medication that should only be used under the supervision of a healthcare professional. It is essential to discuss the potential benefits and risks with a doctor to determine if bumetanide is appropriate for you.
Current Research Limitations
The research on bumetanide's effectiveness in treating neurological disorders is still ongoing. There are gaps in our understanding of its precise mechanism of action, its optimal dosage, and the full range of its benefits and risks. Further research is essential to address these limitations and provide more comprehensive guidance for clinical use.
Future Directions for Research
To advance our understanding of bumetanide and its potential therapeutic value, future research should focus on the following areas: * Elucidating the detailed mechanism of action of bumetanide in various neurological disorders. * Conducting more comprehensive studies to assess the efficacy and safety of bumetanide in different patient populations and disease subtypes. * Developing strategies to optimize the delivery and effectiveness of bumetanide, such as improving its brain penetration. * Exploring the potential for bumetanide in combination therapies with other treatments for neurological disorders.
Conclusion
Bumetanide has emerged as a promising therapeutic agent for certain neurological disorders. However, more research is required to establish its specific roles and limitations. Always consult a healthcare professional to discuss the potential benefits and risks of bumetanide before considering its use. Continued research will be essential to further our understanding of this medication and its potential to improve the lives of those affected by neurological disorders.
Benefit Keywords
Risk Keywords
Article Type
Author: WelzelBjörn, JohneMarie, LöscherWolfgang
Language : English
Author: van AndelDorinde M, SprengersJan J, KönigsMarsh, de JongeMaretha V, BruiningHilgo
Language : English
Author: Juarez-MartinezErika L, van AndelDorinde M, SprengersJan J, AvramieaArthur-Ervin, OranjeBob, ScheepersFloortje E, JansenFloor E, MansvelderHuibert D, Linkenkaer-HansenKlaus, BruiningHilgo
Language : English
Author: HampelPhilip, RömermannKerstin, GailusBjörn, JohneMarie, GerickeBirthe, KaczmarekEdith, LöscherWolfgang
Language : English
Author: van AndelDorinde M, SprengersJan J, OranjeBob, ScheepersFloortje E, JansenFloor E, BruiningHilgo
Language : English
Author: TaoDongxia, LiuFangxi, SunXiaoyu, QuHuiling, ZhaoShanshan, ZhouZhike, XiaoTing, ZhaoChuansheng, ZhaoMei
Language : English
Author: GharaylouZeinab, ShafaghiLida, OghabianMohammad Ali, YoonessiAli, TafakhoriAbbas, Shahsavand AnanlooEsmaeil, HadjighassemMahmoudreza
Language : English
Author: LemonnierE, VilleneuveN, SonieS, SerretS, RosierA, RoueM, BrossetP, ViellardM, BernouxD, RondeauS, ThummlerS, RavelD, Ben-AriY
Language : English
Author: MalamasAnthony S, JinErlei, ZhangQi, HaagaJohn, LuZheng-Rong
Language : English
Author: WangS, ZhangX Q, SongC G, XiaoT, ZhaoM, ZhuG, ZhaoC S
Language : English
Author: TöllnerKathrin, BrandtClaudia, TöpferManuel, BrunhoferGerda, ErkerThomas, GabrielMario, FeitPeter W, LindforsJenna, KailaKai, LöscherWolfgang
Language : English
Author: TöpferManuel, TöllnerKathrin, BrandtClaudia, TweleFriederike, BröerSonja, LöscherWolfgang
Language : English
Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
Author: WuFenfen, MiWentao, CannonStephen C
Language : English
Author: HochmanDaryl W
Language : English
Author: WahabAbdul, AlbusKlaus, HeinemannUwe
Language : English
Author: LemonnierEric, Ben-AriYehezkel
Language : English
Author: BrandtClaudia, NozadzeMaia, HeuchertNina, RattkaMarta, LöscherWolfgang
Language : English
Author: NishimuraMasahiko, KakigiAkinobu, TakedaTaizo, OkadaTeruhiko, DoiKatsumi
Language : English
Bumetanide alleviates epileptogenic and neurotoxic effects of sevoflurane in neonatal rat brain.
Author: EdwardsDavid A, ShahHina P, CaoWengang, GravensteinNikolaus, SeubertChristoph N, MartynyukAnatoly E
Language : English
Author: GlaserNicole, YuenNatalie, AndersonSteven E, TancrediDaniel J, O'DonnellMartha E
Language : English
Author: KilbW, SinningA, LuhmannH J
Language : English
Author: DayiogluEmel, BuharaliogluC Kemal, SaracogluFerit, AkarFatma
Language : English
Author: Młodzik-DanielewiczNatalia, TyrakowskiTomasz
Language : English
Author: Kosik-BogackaDanuta I, BanachBolesław, TyrakowskiTomasz, KozłowskaAlina, KozłowskaSylwia
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.